Side effects of the Mounjaro injection: making an informed choice

The side effects most people actually encounter with the Mounjaro injection

For the majority of people starting tirzepatide, the side effects are digestive. Nausea tends to be the one mentioned most often, followed by an unsettled stomach, loose stools or, in some cases, constipation. Reflux, burping and a feeling of fullness that lingers longer than expected are also common. Fatigue, mild headaches and dizziness appear in trial data too, though less frequently than the GI effects.

The pattern is fairly consistent: symptoms are most noticeable in the first week or two after beginning treatment or stepping up to the next strength. The starting dose of 2.5mg exists partly for this reason, the body gets time to adjust before the therapeutic dose is reached. Titration is paced by your prescriber, not by a fixed calendar, which is one reason clinical oversight across the full course matters. You can read more about the injection itself on the Mounjaro injection overview page.

Injection-site reactions (redness, mild swelling or itching at the spot you injected) are reported by some users. Rotating between the abdomen, thigh and upper arm, and keeping technique consistent, reduces this. There is detailed guidance on injection sites and how choice of location can affect tolerability. One thing patients sometimes mention: a faint altered taste in the mouth after injecting, this is a documented but less widely-known effect worth being aware of before it catches you off guard.

The NHS medicines page for tirzepatide lists the full frequency profile, worth reading alongside the Patient Information Leaflet that arrives with your pen.

Side effects that need urgent medical attention

Most Mounjaro side effects are uncomfortable rather than dangerous. A smaller number are serious enough to need prompt action. Knowing them in advance is not meant to alarm, it is meant to make sure you act quickly if they happen.

Pancreatitis is the one the regulator has been most explicit about. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 receptor agonist medicines, confirming acute pancreatitis as an infrequent but serious risk. The symptom to watch for is severe, persistent abdominal pain that may spread into the back, sometimes accompanied by vomiting. Do not wait for it to pass, go to A&E or call 111.

Gallbladder problems (gallstones, inflammation) are also listed in prescribing information. Symptoms can overlap with pancreatitis (upper-right abdominal pain, nausea, fever) so the same rule applies: get assessed rather than hoping it resolves. Severe dehydration from persistent vomiting or diarrhoea can put strain on the kidneys; staying hydrated and telling a clinician if you cannot keep fluids down matters.

Signs of a serious allergic reaction (throat tightening, facial swelling, rapid heartbeat, difficulty breathing) require emergency care. If you notice anything in this category after injecting, call 999. Full safety information is detailed in the complete guide to Mounjaro injection side effects we maintain on this site.

Reporting side effects and the Yellow Card scheme

If you experience something unexpected while on Mounjaro, two things should happen. First, contact your prescriber, through our aftercare team if you are a nume patient, available seven days a week. Second, consider reporting it to the MHRA directly. The Yellow Card scheme accepts reports from patients as well as clinicians; your account of a side effect contributes to the ongoing safety monitoring that keeps prescribing guidance up to date.

You can also use Yellow Card to flag suspected counterfeit medicines or a seller who appears to be supplying Mounjaro without proper clinical oversight. Mounjaro is a prescription-only medicine and should only reach you through a pharmacy you can verify on the GPhC register.

Tirzepatide carries a Black Triangle designation (▼), meaning the MHRA actively collects additional safety data, which makes patient reporting particularly valuable right now. Our clinical team takes incoming safety reports seriously and can help you decide whether to seek further care.

How side-effect risk fits into the decision to start treatment

No medicine is without trade-offs. The decision to start Mounjaro is a clinical one: how does the risk-benefit balance look for this person, right now? That is what a prescriber is there to assess. The trial data (published across the SURMOUNT programme in the New England Journal of Medicine) shows meaningful average weight reduction for many participants, alongside a documented GI side-effect profile that most people tolerated and that led to discontinuation in a minority.

What tips the balance for most patients is that the digestive effects, whilst real, tend to be temporary and dose-related. Serious events are uncommon. The alternative (untreated excess weight with its associated cardiovascular, metabolic and joint burden) carries its own long-term risk.

If you are weighing this up, our prescribers go through suitability and the full side-effect picture with every patient as part of the consultation process, and a dedicated page covering what are the side effects of Mounjaro injections goes into further detail if you want to read ahead before your appointment. There is no obligation to proceed. For a broader look at how Mounjaro fits alongside other options, the weight-loss treatment overview is a useful starting point. And if cost is part of your thinking, the Mounjaro cost context page explains what private treatment actually includes. Common questions about the process are answered there too.